Sirna Therapeutics to Webcast Presentation at the CIBC World Markets Biotechnology & Specialty Pharmaceuticals Conference
March 28 2006 - 7:45PM
PR Newswire (US)
SAN FRANCISCO, March 28 /PRNewswire-FirstCall/ -- Sirna
Therapeutics, Inc. ("Sirna") (NASDAQ:RNAI), a leading RNAi
therapeutics company, announced today that Howard W. Robin, Sirna's
President and Chief Executive Officer is scheduled to give a
company presentation at the CIBC World Markets Biotechnology &
Specialty Pharmaceuticals Conference, on Tuesday, April 4, 2006 at
1:15 p.m. ET (10:15 a.m. PT) at the Millennium Broadway Hotel in
New York City. A live audio and visual webcast of the presentation
will be available at the Company's corporate web site at
http://www.sirna.com/. Participants are urged to log on to the web
site 15 minutes prior to the scheduled start time to download and
install any necessary audio software. The webcast will also be
archived approximately three hours after the live event and will be
available for 30 days, through July 3, 2006. About Sirna
Therapeutics Sirna Therapeutics is a clinical-stage biotechnology
company developing RNAi-based therapies for serious diseases and
conditions, including age-related macular degeneration (AMD),
hepatitis B and C, dermatology, asthma, Huntington's disease,
diabetes and oncology. Sirna Therapeutics has presented interim
Phase 1 clinical trial data for its most advanced compound,
Sirna-027, a chemically optimized siRNA targeting the clinically
validated vascular endothelial growth factor pathway to treat AMD.
Sirna-027, which has been partnered with Allergan, Inc., has
demonstrated that it is safe and well tolerated with 25 of 26
patients showing visual acuity stabilization and 23% of those
patients experiencing clinically significant improvement in visual
acuity eight weeks after a single injection. In addition, Sirna
recently announced that it has selected Sirna-034, a systemically
delivered, optimized siRNA compound, as its candidate for
advancement to human clinical testing against Hepatitis C virus.
Sirna has a leading intellectual property portfolio in RNAi with 50
issued patents and over 250 pending applications worldwide. More
information on Sirna Therapeutics is available on the Company's web
site at http://www.sirna.com/ . Safe Harbor Statement Statements in
this press release which are not strictly historical are
"forward-looking" statements which should be considered as subject
to many risks and uncertainties. For example, most drug candidates
do not become approved drugs. The development of Sirna-027 and
Sirna-034 as well as Sirna's other programs are still at a
relatively early stage and subject to significant risks and
unknowns. Moreover, Sirna's ability to develop products and operate
as a going concern requires significant cash to fund its operating
programs. Additional risks and uncertainties include Sirna's early
stage of development and short operating history, Sirna's history
and expectation of losses and need to raise capital, the rate at
which Sirna uses cash, the timing of receipt of development
milestone payments from collaborating partners, Sirna's need to
obtain clinical validation and regulatory approval for products,
Sirna's need to obtain and protect intellectual property, risk of
third-party patent infringement claims, Sirna's need to attract and
retain qualified personnel, Sirna's need to engage collaborators,
availability of materials for product manufacturing, the highly
competitive nature of the pharmaceutical market, the limited
trading volume and history of volatility of Sirna's common stock,
Sirna's concentration of stock ownership, and risks from relocating
Sirna headquarters. These and additional risk factors are
identified in Sirna's Securities and Exchange Commission filings,
including the Forms 10-K and 10-Q and in other SEC filings. Sirna
undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may
arise after the date of this release. Contacts: Rebecca Galler
Robison Senior Director, Corporate Strategy Sirna Therapeutics,
Inc. 303-449-6500 Francesca DeMartino The Ruth Group (646) 536-7024
DATASOURCE: Sirna Therapeutics, Inc. CONTACT: Rebecca Galler
Robison, Senior Director, Corporate Strategy of Sirna Therapeutics,
Inc., +1-303-449-6500; or Francesca DeMartino of The Ruth Group,
+1-646-536-7024, , for Sirna Therapeutics, Inc. Web site:
http://www.sirna.com/
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From May 2024 to Jun 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Jun 2023 to Jun 2024